| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-200104150-00002 |
| P698 | PubMed publication ID | 11349712 |
| P50 | author | Camillo Ricordi | Q37383548 |
| Andreas G. Tzakis | Q64162946 | ||
| P2093 | author name string | Miller J | |
| Esquenazi V | |||
| Kupin W | |||
| Rosen A | |||
| Fuller L | |||
| Roth D | |||
| Carreno M | |||
| Ciancio G | |||
| Burke GW 3rd | |||
| Garcia-Morales RO | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 827-835 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Six-year clinical effect of donor bone marrow infusions in renal transplant patients | |
| P478 | volume | 71 |
| Q81865984 | A new method of bone marrow transplantation leads to extension of skin allograft survival |
| Q37282011 | A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab |
| Q37873555 | Achievements and challenges in composite tissue allotransplantation |
| Q80813568 | Allogeneic donor bone marrow cells recovery and infusion after allogeneic face transplantation from the same donor |
| Q34842525 | Bone marrow transfusions in cadaver renal allografts: pilot trials with concurrent controls |
| Q33742259 | Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes |
| Q77847861 | Cell-based therapies go live |
| Q43873016 | Co-infusion of donor adipose tissue-derived mesenchymal and hematopoietic stem cells helps safe minimization of immunosuppression in renal transplantation - single center experience |
| Q46440457 | Composite osseomusculocutaneous sternum, ribs, thymus, pectoralis muscles, and skin allotransplantation model of bone marrow transplantation. |
| Q36708274 | Composite tissue allotransplantation immunology |
| Q33213652 | Different routes of donor-derived hematopoietic stem cell transplantation for donor-specific chimerism induction across MHC barrier. |
| Q47976224 | Donor Age and Gender Are the Strongest Predictors of Marrow Recovery from Cadaveric Vertebral Bodies |
| Q73143743 | Donor bone marrow infusion in cadaveric renal transplantation |
| Q35893653 | Donor bone marrow transplantation: chimerism and tolerance |
| Q35877014 | Donor-derived peripheral mononuclear cell DNA is associated with stable kidney allograft function: a randomized controlled trial. |
| Q80486493 | Donor-origin cell engraftment after intraosseous or intravenous bone marrow transplantation in a rat model |
| Q41820518 | Evaluation of the tolerogenic effects of donor bone marrow cells using a severe combined immunodeficient mouse-human islet transplant model |
| Q37355472 | Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients |
| Q27005853 | Face allotransplantation and burns: a review |
| Q37196119 | Five-year clinical effects of donor bone marrow cells infusions in kidney allograft recipients: improved graft function and higher graft survival |
| Q41122546 | Hand allotransplantation |
| Q38935186 | Hematopoietic stem cells and solid organ transplantation |
| Q37958357 | How reconstructive transplantation is different from organ transplantation--and how it is not. |
| Q78733934 | Human donor bone marrow cells induce in vitro "suppressor T cells" that functionally suppress autologous B cells |
| Q33867234 | Immune "tolerance profiles" in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays |
| Q35216479 | Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation |
| Q36308116 | Immune tolerance in pancreatic islet xenotransplantation |
| Q37811391 | Immunologic Aspects and Rejection in Solid Organ Versus Reconstructive Transplantation |
| Q74389388 | Immunoregulatory role of chimerism in clinical organ transplantation |
| Q37025883 | Induction therapy in renal transplantation : an overview of current developments |
| Q36368247 | Insulin-secreting cells derived from stem cells: clinical perspectives, hypes and hopes |
| Q37331781 | Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect? |
| Q47871456 | Microchimerism and renal transplantation: doubt still persists |
| Q37888423 | Microchimerism in promoting graft acceptance in clinical transplantation. |
| Q38053175 | Minimizing immunosuppression in hand transplantation |
| Q35877027 | Mixed chimerism and split tolerance: mechanisms and clinical correlations |
| Q74681820 | Normal donor bone marrow is superior to Flt3 ligand-mobilized bone marrow in prolonging heart allograft survival when combined with anti-CD40L (CD154) |
| Q77370553 | Perioperative donor bone marrow infusion in cadaver kidney transplant recipients |
| Q37373575 | Portal venous donor-specific transfusion in conjunction with sirolimus prolongs renal allograft survival in nonhuman primates |
| Q35687839 | Prospects and strategies for clinical tolerance |
| Q83400772 | Regulatory T-cell subset analysis and profile of interleukin (IL)-10, IL-17 and interferon-gamma cytokine-producing cells in kidney allograft recipients with donor cells infusion |
| Q34487772 | STEALTH matters: a novel paradigm of durable primate allograft tolerance |
| Q83725199 | Serum levels of interleukin (IL)-10, IL-17, transforming growth factor (TGF)-β1, and interferon-γ cytokines and expression levels of IL-10 and TGF-β1 genes in renal allograft recipients after donor bone marrow cell infusion |
| Q37656274 | Should microchimerism turn into rejection prophylactics? |
| Q35106129 | Should we be performing more combined hematopoietic stem cell plus solid organ transplants? |
| Q50491205 | Stable renal engraftment in a patient following successful tandem autologous/reduced-intensity conditioning allogeneic transplantation for treatment of multiple myeloma with del(17p) that developed as a post-transplantation lymphoproliferative disea |
| Q35990853 | Strategies for minimizing immunosuppression in kidney transplantation |
| Q43274504 | TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion. |
| Q38228330 | The applications of bone marrow-derived stem cells to induce tolerance and chimerism in organ transplantation |
| Q37813564 | The immunosuppressive pipeline: Meeting unmet needs in liver transplantation |
| Q38515087 | The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation |
| Q37403731 | Translating transplantation tolerance in the clinic: where are we, where do we go? |
| Q33888754 | Upper extremity transplantation: current concepts and challenges in an emerging field |
| Q34171957 | Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression |
| Q26992026 | Vascularized composite tissue allotransplantation--state of the art |
Search more.